XML 24 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Certain Balance Sheet Items (Notes)
9 Months Ended
Sep. 30, 2016
Balance Sheet Related Disclosures [Abstract]  
Certain Balance Sheet Items
Certain Balance Sheet Items
Accounts receivable, net consisted of the following (in thousands):
 
 
September 30,
2016
 
December 31,
2015
Accounts receivable from product sales to collaborators
 
$
10,220

 
$
4,996

Accounts receivable from other product sales
 
1,912

 
2,442

Accounts receivable from revenues under collaborative agreements
 
5,937

 
25,939

     Subtotal
 
18,069

 
33,377

Allowance for distribution fees and discounts
 
(390
)
 
(967
)
     Total accounts receivable, net
 
$
17,679

 
$
32,410


Inventories consisted of the following (in thousands):
 
 
September 30,
2016
 
December 31,
2015
Raw materials
 
$
1,490

 
$
677

Work-in-process, net
 
9,708

 
8,481

Finished goods
 
1,654

 
331

     Total inventories
 
$
12,852

 
$
9,489


Prepaid expenses and other assets consisted of the following (in thousands):
 
 
September 30,
2016
 
December 31,
2015
Prepaid research and development expenses
 
$
8,801

 
$
9,225

Other prepaid expenses
 
1,810

 
1,198

Other assets
 
437

 
530

     Total prepaid expenses and other assets
 
11,048

 
10,953

Less long-term portion
 
4,986

 
5,574

     Total prepaid expenses and other assets, current
 
$
6,062

 
$
5,379


Property and equipment, net consisted of the following (in thousands):
 
 
September 30,
2016
 
December 31,
2015
Research equipment
 
$
10,316

 
$
9,666

Computer and office equipment
 
3,178

 
2,570

Leasehold improvements
 
2,319

 
2,025

     Subtotal
 
15,813

 
14,261

Accumulated depreciation and amortization
 
(11,406
)
 
(10,318
)
     Property and equipment, net
 
$
4,407

 
$
3,943

Depreciation and amortization expense totaled $0.7 million and $0.4 million for the three months ended September 30, 2016 and 2015, respectively, and $1.8 million and $1.2 million for the nine months ended September 30, 2016 and 2015, respectively.
Accrued expenses consisted of the following (in thousands):
 
 
September 30,
2016
 
December 31,
2015
Accrued outsourced research and development expenses
 
$
9,947

 
$
8,617

Accrued compensation and payroll taxes
 
8,201

 
8,636

Accrued outsourced manufacturing expenses
 
3,706

 
6,205

Other accrued expenses
 
3,890

 
4,118

     Total accrued expenses
 
25,744

 
27,576

Less long-term accrued outsourced research and development expenses
 
11

 
784

     Total accrued expenses, current
 
$
25,733

 
$
26,792


Long-term accrued outsourced research and development is included in other long-term liabilities in the condensed consolidated balance sheets.
Deferred revenue consisted of the following (in thousands):
 
 
September 30,
2016
 
December 31,
2015
Collaborative agreements
 
 
 
 
License fees and event-based payments:
 
 
 
 
Roche
 
$
36,542

 
$
39,038

Other
 
8,400

 
9,724

 
 
44,942

 
48,762

Reimbursement for research and development services
 
5,799

 
4,461

Total deferred revenue
 
50,741

 
53,223

Less current portion
 
9,892

 
9,304

Deferred revenue, net of current portion
 
$
40,849

 
$
43,919